AR122323A1 - Compuesto de niclosamida, composición que lo comprende y cocristal - Google Patents

Compuesto de niclosamida, composición que lo comprende y cocristal

Info

Publication number
AR122323A1
AR122323A1 ARP200102884A ARP200102884A AR122323A1 AR 122323 A1 AR122323 A1 AR 122323A1 AR P200102884 A ARP200102884 A AR P200102884A AR P200102884 A ARP200102884 A AR P200102884A AR 122323 A1 AR122323 A1 AR 122323A1
Authority
AR
Argentina
Prior art keywords
particle size
cocrystal
niclosamide
composition
range
Prior art date
Application number
ARP200102884A
Other languages
English (en)
Inventor
Gary Glick
Jr Anthony W Opipari
Original Assignee
First Wave Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Wave Bio Inc filed Critical First Wave Bio Inc
Publication of AR122323A1 publication Critical patent/AR122323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta divulgación muestra compuestos de niclosamida (o sales y/o cocristales farmacéuticamente aceptables de estos, p. ej., niclosamida) que tienen una o más propiedades que incluyen, a mero título enunciativo: una pureza en particular (p. ej., una pureza química mayor que aproximadamente 99,0%) y un tamaño de partículas en particular (p. ej., una distribución del tamaño de partículas en particular y/o un margen del tamaño de partículas en particular y/o un margen del área de la superficie específico).
ARP200102884A 2019-10-18 2020-10-19 Compuesto de niclosamida, composición que lo comprende y cocristal AR122323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962923290P 2019-10-18 2019-10-18

Publications (1)

Publication Number Publication Date
AR122323A1 true AR122323A1 (es) 2022-08-31

Family

ID=75492817

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102884A AR122323A1 (es) 2019-10-18 2020-10-19 Compuesto de niclosamida, composición que lo comprende y cocristal

Country Status (9)

Country Link
US (1) US20210114973A1 (es)
EP (1) EP4045480A4 (es)
JP (1) JP2022553934A (es)
KR (1) KR20240039083A (es)
CN (1) CN117597327A (es)
AR (1) AR122323A1 (es)
CA (1) CA3157861A1 (es)
TW (1) TW202128610A (es)
WO (1) WO2021076922A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003251A (es) 2014-09-12 2017-12-20 Antibiotx Aps Uso antibacteriano de salicilanilidas halogenadas.
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN109562137A (zh) 2015-09-01 2019-04-02 第波生物公司 用于治疗与异常炎性反应有关的病况的方法和组合物
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US20230107927A1 (en) * 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
EP4397371A2 (en) 2020-05-19 2024-07-10 Cybin IRL Limited Deuterated tryptamine derivatives and methods of use
CN113768937B (zh) * 2021-11-15 2022-04-08 恒翼生物医药科技(上海)有限公司 用于降低尿酸水平的化合物
GB202301306D0 (en) * 2023-01-30 2023-03-15 Ucl Business Ltd Treatment of granulomatous disease
CN117466786A (zh) * 2023-12-25 2024-01-30 湖南一格制药有限公司 盐酸戊乙奎醚杂质及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557615C2 (de) * 1975-12-20 1985-08-14 Bayer Ag, 5090 Leverkusen Neue Niclosamid-Suspensionsformulierungen
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
WO2004006906A2 (en) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
CN1546919A (zh) * 2003-07-13 2004-11-17 叶声羽 桑拿浴房
CN1626506A (zh) * 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
CN103751854B (zh) * 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
EP3168211A1 (en) * 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide

Also Published As

Publication number Publication date
JP2022553934A (ja) 2022-12-27
KR20240039083A (ko) 2024-03-26
EP4045480A4 (en) 2023-11-22
CA3157861A1 (en) 2021-04-22
TW202128610A (zh) 2021-08-01
US20210114973A1 (en) 2021-04-22
EP4045480A1 (en) 2022-08-24
WO2021076922A1 (en) 2021-04-22
CN117597327A (zh) 2024-02-23

Similar Documents

Publication Publication Date Title
AR122323A1 (es) Compuesto de niclosamida, composición que lo comprende y cocristal
CL2019003610A1 (es) Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477).
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CL2020003101A1 (es) Sales de sepiapterina farmacéuticamente aceptables.
CO2020007018A2 (es) Proceso para preparar tapinarof
CO2021017343A2 (es) Formas de sales cristalinas de un inhibidor de cinasas
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
ECSP20063701A (es) Formulación sólida de mezclas insecticidas
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
AR114270A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
CO2021002721A2 (es) Suspensiones líquidas de paracetamol
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
BR112018003313A2 (pt) novo derivado de catecol e composição farmacêutica compreendendo o mesmo